Introduction
My focus
I have extensive experience advising private investment funds and strategic buyers in critical business matters and strategic transactions, acquisitions and divestitures, joint ventures, and strategic alliances.
In addition, I work with private companies and financial sponsors in the management of their portfolio companies on a variety of corporate matters, including add-on acquisitions, strategic ventures, debt financings, and international expansions.
Finally, I have significant experience working on strategic ventures with large corporations, including their preferred stock and convertible debt financings and exit transactions of their portfolio companies.
Representative experience
Daniel joined Nixon Peabody in March 2022. The work outlined below may reflect experience from prior firms.
- Represented Halma plc, a UK global group of life-saving technology companies that provide innovative solutions to key problems facing the world today, in its acquisition of PeriGen, a leader in artificial intelligence, medical, and health technology space
- Represented Carlyle affiliated funds and portfolio companies in several add-on acquisitions for its cloud-based business technology and intelligence platform
- Represented Unilever PLC in strategic acquisitions and divestitures
- Represented Globant, a global, publicly traded digitally native company in add-on acquisitions, including those providing innovative technology solutions in the fraud prevention and identity protection space
- Represented Cerberus Capital in acquisitions in the advertising and food services industries
- Represented BTG plc, the global specialist healthcare company, in various acquisitions, including its acquisition of Novate Medical, a medical device company headquartered in Ireland, and in its investment and option to acquire Veran Medical Technologies, an early lung cancer diagnoses company
- Represented SK Capital Partners in its acquisitions of various portfolio companies in the specialty materials, chemicals, and pharmaceuticals sectors, including Foremark Performance Chemicals, Tri-Tex Co., Noramco, and Tasmanian Alkaloids
- Represented Seaspan Corporation, a leading independent charter owner and operator of containerships, in its acquisition of APR Energy Limited, a global leasing business that owns and operates a fleet of gas turbines and other power generation equipment
- Represented Merck & Co. and Merck Global Health Innovation Fund in several strategic acquisitions and venture financings in the health technology and pharma space
- Represented Comcast Corporation and Comcast Ventures in several strategic acquisition and venture financings in the media tech and infrastructure space
Looking ahead
I see continued competition among and between private and public buyers to win deals in a competitive market environment, particularly in the growing and robust middle-market, with financial sponsors successfully building on platform acquisitions in key sectors. On the strategic side, I see multinational companies rapidly evolving in the deal-making arena, as the pressure to execute on expansion goals in the US and abroad has resulted in increasingly sophisticated corporate development teams.
In the news
- Mergers & Acquisitions
The dark side of dealmaking
May 13, 2024This article covers unconventional strategies and tactics that are emerging for dealmakers as they navigate uncertainty around valuations and liquidity. New York City Corporate partners Kevin Grant, co-leader of the M&A and Corporate Transactions team, and Dan Belostock discuss the highly structured nature of deals as parties have become more risk adverse, and some of the various tactics that are gaining steam with buyers and sellers.
- Law360
Healthcare attorneys turn attention to material adverse change
This article covers the prevalence of material adverse change (MAC) clauses in life sciences M&A contracts and how companies are approaching them. New York City Corporate partner Dan Belostock, a member of NP’s M&A and Private Equity teams, discusses how longer timelines for deals to close require attorneys to think more about MAC clauses today than before, noting that litigation focuses on MAC clauses isn’t very common.April 30, 2024 - Law360
UK safety biz Halma buys medical tool maker for $89 million
Dec 20, 2023This article mentions NP for representing Halma PLC in its acquisition of TeDan, a group of companies that develop, manufacture, and supply medical devices to surgeons. The NP deal team was led by New York City Corporate partner Dan Belostock and also included Corporate partners Alexandra Lopez-Casero and Thomas McCord of Boston, Kevin Grant of New York City, and Shahzad Malik of Los Angeles; Boston Government Investigations & White-Collar Defense partners Hannah Bornstein and Brian French; Boston Labor & Employment partner Jeff Gilbreth; Los Angeles Intellectual Property partner Seth Levy; Rochester Privacy & Technology counsel Jenny Holmes and Boston Corporate counsel David Crosby; Corporate associates Brian Kenney of Washington, DC and Tim Sharkey of New York City; Chicago IP associates Ben Rosborough and Eliana Torres; Los Angeles Labor & Employment associate Alice Kwak; Chicago IP senior paralegal Tim Fiester; and Chicago Corporate paralegal Astrid McGruder.
- Crain’s New York Business
People on the move
New York City Corporate partners Kevin Grant and Dan Belostock are featured in this article for their recent arrival to NP, noting their focus on middle-market M&A and private equity transactions and providing additional detail on their practices.March 28, 2022 - The Deal
Movers & Shakers: DLA pair joins Nixon Peabody
New York City Corporate partners Kevin Grant and Daniel Belostock are featured in this column for their move to Nixon Peabody, mentioning their practice focus areas as well as details from prior work experience and education. The article notes that Kevin returns to NP after beginning his career at the firm as an associate.March 10, 2022 - Bloomberg Law
Wake up call
The following news coverage features the arrival of New York City Corporate partners Kevin Grant and Daniel Belostock to Nixon Peabody, mentioning that Kevin returns to NP after beginning his career at the firm as an associate.March 10, 2022 - New York Law Journal
On the move
The following news coverage features the arrival of New York City Corporate partners Kevin Grant and Daniel Belostock to Nixon Peabody, mentioning that Kevin returns to NP after beginning his career at the firm as an associate.March 9, 2022
Admitted to practice
New Jersey
New York
Education
Harvard Law School, J.D.
Rutgers University, B.A.
Recognition
- Recommended in The Legal 500 United States 2023 editorial for M&A/corporate and commercial—M&A: middle-market (sub-$500m)
Insights And Happenings
View AllProfessionals in the Practice Area
View AllJohn P. Beals
Partner/Co-leader, Investment Funds Practice- Boston
- Office:+1 617.345.1060
- jbeals@nixonpeabody.com
-
Benedict Kwon
Partner / Co-leader, Investment Funds Practice- Los Angeles
- Office:+1 213.629.6164
- bkwon@nixonpeabody.com
-
